ccdc39 Antibody

What is CCDC39 and why is it important in ciliary research?

CCDC39 is a core axonemal protein that plays an essential role in assembling inner dynein arms (IDAs) and the dynein regulatory complex in motile cilia. It is critical for establishing the 96 nm repeats along the ciliary axoneme in conjunction with CCDC40. CCDC39's importance lies in its role in cilia motility, as variants in this gene can cause defective cilia beat regulation and ciliary immobility. Mutations in CCDC39 are associated with Primary Ciliary Dyskinesia (PCD), characterized by chronic bronchitis, recurrent respiratory infections, situs inversus, and male infertility. Understanding CCDC39's function through antibody-based detection methods has become fundamental to ciliopathy research .

What are the typical applications for CCDC39 antibodies in research?

CCDC39 antibodies are primarily used in Western blotting to detect protein expression levels in various tissues, particularly in ciliated cells. They can also be employed in immunohistochemistry to visualize CCDC39 localization within cilia structures. ELISA applications are helpful for quantitative assessment of CCDC39 levels. For investigating ciliary ultrastructure abnormalities associated with CCDC39 mutations, these antibodies can be used alongside electron microscopy techniques to correlate protein expression with structural defects. Importantly, multiple antibody formats (unconjugated, biotin-conjugated, and fluorophore-conjugated) are available for different experimental needs .

How can I determine if my tissue sample expresses CCDC39?

To determine CCDC39 expression in your tissue sample, Western blotting represents the most straightforward approach. Prepare protein lysates from your sample following standard protocols. Run 10-20 μg of protein on SDS-PAGE, then transfer to a PVDF membrane. Block with 5% defatted milk diluted in TBST, then incubate with anti-CCDC39 primary antibody (1:1000 dilution) at 4°C overnight. After washing, incubate with an appropriate secondary antibody at 37°C for 2 hours, then detect using enhanced chemiluminescence. Include β-actin (1:8000, ab8224) as a loading control. CCDC39 antibodies targeting the C-terminal region (amino acids 770-798) are particularly effective for detection in human, mouse, and hamster samples .

How can CCDC39 antibodies help determine the molecular basis of ciliary defects in PCD?

CCDC39 antibodies provide critical insights into the molecular pathology of PCD by enabling researchers to correlate genetic mutations with protein expression and localization abnormalities. In comparative studies of wild-type versus mutant samples, these antibodies can reveal whether CCDC39 mutations result in protein absence, truncation, or mislocalization. As demonstrated in research using sperm samples from PCD patients, Western blotting with CCDC39 antibodies showed significantly lower protein levels in affected individuals compared to controls. This approach allows researchers to establish direct connections between specific genetic variants (such as c.286C>T:p.Arg96Ter or c.732_733del:p.Ala245PhefsTer18) and protein expression defects. Combined with electron microscopy, immunolocalization studies can reveal how CCDC39 deficiency disrupts dynein arm assembly and axonemal organization .

What are the considerations for using CCDC39 antibodies in multi-protein complex studies?

When investigating CCDC39's interactions within protein complexes, researchers should consider several methodological factors. First, select antibodies with epitopes that don't interfere with protein-protein interaction domains; C-terminal targeting antibodies (amino acids 770-798) are often preferable. For co-immunoprecipitation studies, use gentle lysis buffers that preserve protein-protein interactions. Consider crosslinking approaches to stabilize transient interactions before immunoprecipitation. When examining CCDC39's relationship with CCDC40, which together form a complex crucial for 96 nm microtubule structural repeats, ensure that extraction conditions maintain the integrity of these interactions. Proximity ligation assays using fluorophore-conjugated CCDC39 antibodies can provide spatial resolution of protein interactions within the axonemal structure. Always validate antibody specificity using knockout/knockdown controls to avoid false positive interactions .

How can fluorescently conjugated CCDC39 antibodies be used to study ciliary dynamics?

Fluorescently conjugated CCDC39 antibodies enable advanced live or fixed-cell imaging approaches for studying ciliary dynamics. When using AbBy Fluor® 594, 555, 647, or 680 conjugated antibodies, researchers can perform time-lapse microscopy to track CCDC39 localization during ciliogenesis in vitro. For multi-color imaging, combine CCDC39 antibodies (e.g., AbBy Fluor® 594-conjugated) with antibodies against other ciliary markers like acetylated α-tubulin (axoneme) and γ-tubulin (basal bodies). This approach allows visualization of CCDC39 in relation to other ciliary structures. For quantitative analysis, measure fluorescence intensity along the ciliary axoneme to determine the distribution pattern of CCDC39. In developing ependymal cells, this technique has revealed that CCDC39 deficiency affects not only protein localization but also cilia number and morphology, with mutants showing increased cilia density (29.2±2.4 per cell versus 16.4±1.1 in wild type) .

What are the optimal conditions for Western blotting with CCDC39 antibodies?

For optimal Western blotting results with CCDC39 antibodies, protein extraction requires careful consideration of sample type. For ciliated cell samples such as respiratory epithelial cells or sperm, use buffers containing non-ionic detergents (0.5% NP-40 or Triton X-100) to effectively extract axonemal proteins. Load 10-20 μg of protein per lane on 7-10% SDS-PAGE gels since CCDC39 is a relatively large protein (~99 kDa). Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer with 10% methanol. Block with 5% defatted milk in TBST for 1 hour at room temperature. For primary antibody incubation, use anti-CCDC39 at 1:1000 dilution overnight at 4°C. After washing, apply HRP-conjugated secondary antibody at 1:5000 for 2 hours at room temperature. When analyzing CCDC39 mutants, be aware that truncated proteins may require different gel concentrations for optimal separation. Including both positive (wild-type) and negative (known CCDC39-deficient) controls is essential for accurate interpretation .

How should researchers prepare axoneme samples for CCDC39 antibody-based detection?

Axoneme preparation for CCDC39 antibody detection requires specialized techniques to preserve structural integrity. For ciliated cells, isolate axonemes using a detergent-based method: wash cells in PBS, then treat with 0.5% Triton X-100 in stabilization buffer (50 mM HEPES, 50 mM PIPES, 1 mM EGTA, 1 mM MgSO4, pH 7.0) for 5 minutes. Centrifuge at 1500g for 5 minutes to pellet axonemes. For studies comparing different experimental conditions, ensure consistent treatment; research has shown that temperature shifts (e.g., from 21°C to 32°C) can affect CCDC39 expression and localization in axonemes. When preparing sperm flagella, additional steps may be needed: treat samples with 0.2% Triton X-100 in buffer containing DNase I to remove nuclear and cytoplasmic contamination before centrifugation. For Western blotting of axonemal preparations, load approximately 10 μg total protein per lane and include α-tubulin as a loading control .

What controls should be included when using CCDC39 antibodies in ciliopathy research?

Comprehensive controls are essential when using CCDC39 antibodies in ciliopathy research. First, include tissue-specific positive controls known to express CCDC39 (respiratory epithelium, testis, or brain ependymal cells). For negative controls, use tissues from verified CCDC39 knockout/mutant models or CCDC39-siRNA treated cells. When studying patient samples, incorporate age and sex-matched healthy controls. For specificity validation, perform peptide competition assays using the immunizing peptide (amino acids 770-798 for C-terminal antibodies). In co-labeling experiments, include antibodies against related structures—DNALI1 for inner dynein arms and GAS8 for the nexin-dynein regulatory complex—to confirm expected co-localization patterns. Research has shown that DNALI1 fails to localize to cilia in CCDC39-deficient cells while accumulating in the cytoplasm, providing a functional readout of CCDC39 deficiency. To control for developmental timing effects in studies of multiciliated cells, carefully match wild-type and mutant samples for developmental stage, as CCDC39 phenotypes can become more pronounced with age (e.g., P9 versus P0/P1) .

What are the common reasons for weak or absent CCDC39 signal in Western blotting?

When encountering weak or absent CCDC39 signals in Western blotting, several methodological issues may be responsible. First, consider protein degradation—CCDC39 is a large protein (~99 kDa) susceptible to proteolysis, so ensure fresh sample preparation with complete protease inhibitor cocktails. Second, extraction efficiency may be insufficient; axonemal proteins require specialized buffers, so try increasing detergent concentration to 1% NP-40 or adding 0.1% SDS to improve extraction. Third, antibody concentration may be suboptimal; if using the standard 1:1000 dilution yields weak signals, titrate to 1:500 or even 1:250. Transfer efficiency can be problematic for large proteins, so extend transfer time to 2 hours or reduce methanol concentration in transfer buffer. For tissue-specific issues, note that CCDC39 expression varies significantly between tissues; respiratory epithelium and testis typically show stronger expression than other tissues. Finally, genetic mutations affecting transcript stability can reduce protein levels—research has shown that splice site mutations (e.g., c.930+2T>A) can reduce CCDC39 mRNA to 30% of wild-type levels .

How can researchers differentiate between primary and secondary effects of CCDC39 deficiency?

Differentiating primary from secondary effects of CCDC39 deficiency requires systematic experimental approaches. First, perform temporal analysis using inducible knockout models or time-course studies to determine which defects appear earliest after CCDC39 depletion. Second, implement rescue experiments by re-expressing wild-type CCDC39 in deficient cells to identify which phenotypes are directly reversed. Third, conduct protein interaction studies using co-immunoprecipitation with CCDC39 antibodies to identify direct binding partners versus indirectly affected proteins. Fourth, use proximity ligation assays to confirm spatial relationships between CCDC39 and suspected interaction partners in situ. Research has established that CCDC39 directly affects inner dynein arm assembly (primary effect), while central microtubule pair defects may represent secondary consequences. Tissue-specific differences in phenotype severity (e.g., ependymal versus respiratory versus choroid plexus cilia) further reveal context-dependent roles—choroid plexus cilia showed no differences in DNALI1 or GAS8 immunostaining in CCDC39 mutants, while ependymal and respiratory cilia showed clear defects .

How can researchers address non-specific binding with CCDC39 antibodies?

Non-specific binding with CCDC39 antibodies can compromise experimental interpretation but can be addressed through several optimization strategies. First, increase blocking stringency by extending blocking time to 2 hours and using 5% BSA instead of milk for phosphorylation-sensitive applications. Second, optimize antibody concentration through titration experiments; while 1:1000 is standard, some applications may require higher dilutions (1:2000-1:5000) to reduce background. Third, increase washing stringency with higher salt TBST (0.1% to 0.3% Tween-20) and extend wash times to 10 minutes per wash with at least 4-5 washes. Fourth, pre-absorb antibodies against acetone powder of CCDC39-knockout tissue to remove cross-reactive antibodies. For Western blots, compare band patterns between different antibodies targeting distinct CCDC39 epitopes (e.g., C-terminal versus mid-region) to confirm specificity. When using fluorescently conjugated antibodies, include appropriate isotype controls and single-stained samples to correct for spectral overlap. Always validate antibody specificity using siRNA knockdown or CRISPR knockout controls where possible .

How should researchers interpret CCDC39 expression data from different ciliated tissues?

Interpreting CCDC39 expression data across different ciliated tissues requires careful consideration of tissue-specific contexts. Comparative analysis has revealed significant variability in CCDC39 function and localization patterns between tissues. In ependymal cells, CCDC39 deficiency causes severe ultrastructural defects and absence of DNALI1 and GAS8 in cilia, while choroid plexus cilia show no detectable differences in these markers despite the same genetic mutation. Respiratory cilia exhibit an intermediate phenotype with lack of DNALI1 but normal GAS8 expression. These tissue-specific differences suggest context-dependent roles for CCDC39 in ciliogenesis and maintenance. When quantifying expression levels, normalize to tissue-specific reference genes rather than ubiquitous controls, as ciliary gene expression varies significantly between tissues. Additionally, developmental timing affects CCDC39 expression and phenotypes—the impact of CCDC39 deficiency becomes more pronounced at later developmental stages (P9 versus P0/P1). Therefore, when comparing tissues, match developmental stages as closely as possible and avoid cross-tissue comparisons without appropriate controls .

What insights can CCDC39 antibody studies provide about the pathogenesis of Primary Ciliary Dyskinesia?

CCDC39 antibody studies offer crucial insights into Primary Ciliary Dyskinesia (PCD) pathogenesis by revealing the molecular and structural consequences of CCDC39 mutations. Immunohistochemical analysis using these antibodies has demonstrated that CCDC39-deficient cilia lack inner dynein arms while retaining outer dynein arms, explaining the specific motility defects seen in patients. Transmission electron microscopy correlated with CCDC39 immunolabeling has revealed that mutant cilia exhibit disorganized microtubules with aberrant arrangements (8+2, 9+0) instead of the normal 9+2 configuration, and are significantly thinner (298.7±7.3 nm versus 372.6±4.8 nm in wild type). Interestingly, CCDC39 deficiency leads to increased cilia density (29.2±2.4 per cell versus 16.4±1.1 in wild type), suggesting compensatory mechanisms or disrupted centriole/deuterosome regulation. Western blotting has confirmed that different mutation types (nonsense, frameshift, duplications) result in variable protein expression levels, explaining phenotypic heterogeneity among patients. In sperm studies, CCDC39 mutations have been linked to multiple morphological abnormalities of sperm flagella, establishing a direct connection between the same molecular defect and both respiratory and fertility problems in PCD patients .

How can researchers use CCDC39 antibodies to investigate relationships between cilia structure and function?

CCDC39 antibodies enable detailed investigation of structure-function relationships in motile cilia through several advanced approaches. By combining immunofluorescence with high-speed videomicroscopy, researchers can correlate CCDC39 localization patterns with specific motility parameters such as beat frequency and waveform characteristics. Multi-color immunofluorescence with CCDC39 antibodies alongside markers for dynein arms (DNALI1), nexin links (GAS8), and axonemal structure (acetylated α-tubulin) allows quantitative analysis of protein co-localization and its relationship to functional outcomes. Super-resolution microscopy with fluorophore-conjugated CCDC39 antibodies can resolve the precise arrangement of CCDC39 within the 96 nm repeating units along the axoneme. Correlative light and electron microscopy (CLEM) using CCDC39 antibodies linked to electron-dense markers enables direct visualization of how CCDC39 deficiency affects ultrastructure. Research has established that CCDC39 functions with CCDC40 to define binding sites for radial spokes along peripheral microtubules and provide anchoring sites for inner dynein arms and nexin-dynein regulatory complexes. This organizational role explains why CCDC39 deficiency causes both structural abnormalities (disorganized microtubules) and functional defects (immotile cilia) in a coordinated manner .